LT2961410T - Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus - Google Patents

Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus

Info

Publication number: LT2961410T
Authority: LT; Lithuania
Prior art keywords: pyazolophyrimidine; pi3k; derivatives; treatment; related disorders
Prior art date: 2013-03-01

Application number

LTEP14710739.5T

Other languages

English (en)

Inventor

Yun-Long Li

Wenqing Yao

Andrew P. Combs

Eddy W. Yue

Song MEI

Wenyu Zhu

Joseph Glenn

Maduskuie, Jr.

Richard B. Sparks

Brent Douty

Chunhong He

Original Assignee

Incyte Holdings Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-01

Filing date

2014-02-28

Publication date

2020-02-10

2014-02-28 Application filed by Incyte Holdings Corporation filed Critical Incyte Holdings Corporation

2020-02-10 Publication of LT2961410T publication Critical patent/LT2961410T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

LTEP14710739.5T 2013-03-01 2014-02-28 Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus LT2961410T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361771480P	2013-03-01	2013-03-01
PCT/US2014/019372 WO2014134426A1 (en)	2013-03-01	2014-02-28	USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS

Publications (1)

Publication Number	Publication Date
LT2961410T true LT2961410T (lt)	2020-02-10

Family

ID=50288319

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP14710739.5T LT2961410T (lt)	2013-03-01	2014-02-28	Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus

Country Status (32)

Country	Link
US (6)	US9932341B2 (lt)
EP (3)	EP2961410B1 (lt)
JP (5)	JP6545106B2 (lt)
KR (5)	KR20240152422A (lt)
CN (2)	CN105120871B (lt)
AR (1)	AR094964A1 (lt)
AU (5)	AU2014223257B2 (lt)
BR (1)	BR112015020941A2 (lt)
CA (1)	CA2901993C (lt)
CL (1)	CL2015002442A1 (lt)
CR (1)	CR20150472A (lt)
CY (1)	CY1122712T1 (lt)
DK (1)	DK2961410T3 (lt)
EA (2)	EA202192151A1 (lt)
ES (2)	ES2945212T3 (lt)
HR (1)	HRP20200263T1 (lt)
HU (1)	HUE047719T2 (lt)
IL (6)	IL311666A (lt)
LT (1)	LT2961410T (lt)
MX (2)	MX367713B (lt)
MY (1)	MY177875A (lt)
PE (1)	PE20151996A1 (lt)
PH (3)	PH12021552233A1 (lt)
PL (1)	PL2961410T3 (lt)
PT (1)	PT2961410T (lt)
RS (1)	RS59958B1 (lt)
SG (3)	SG10201707130UA (lt)
SI (1)	SI2961410T1 (lt)
SM (1)	SMT202000043T1 (lt)
TW (5)	TWI657090B (lt)
UA (1)	UA119641C2 (lt)
WO (1)	WO2014134426A1 (lt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2766100C (en)	2009-06-29	2018-05-22	Incyte Corporation	Pyrimidinones as pi3k inhibitors
KR102131612B1 (ko)	2011-09-02	2020-07-08	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014110574A1 (en)	2013-01-14	2014-07-17	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es)	2013-01-15	2020-10-27	Incyte Holdings Corp	Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
TWI657090B (zh)	2013-03-01	2019-04-21	英塞特控股公司	吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
US9556197B2 (en)	2013-08-23	2017-01-31	Incyte Corporation	Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
LT3129021T (lt)	2014-04-08	2020-12-10	Incyte Corporation	B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016010897A1 (en)	2014-07-14	2016-01-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016130501A1 (en)	2015-02-09	2016-08-18	Incyte Corporation	Aza-heteroaryl compounds as pi3k-gamma inhibitors
SI3831833T1 (sl) *	2015-02-27	2023-03-31	Incyte Holdings Corporation	Postopki za pripravo inhibitorja PI3K
WO2016183063A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Crystalline forms of a pi3k inhibitor
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es)	2015-09-09	2017-11-29	Incyte Corp	Sales de un inhibidor de pim quinasa
WO2017059251A1 (en)	2015-10-02	2017-04-06	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
US10065963B2 (en)	2015-11-06	2018-09-04	Incyte Corporation	Heterocyclic compounds as PI3K-γ inhibitors
ES2833955T3 (es)	2016-01-05	2021-06-16	Incyte Corp	Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
KR102375929B1 (ko)	2016-03-31	2022-03-16	온크터널 테라퓨틱스, 인코포레이티드.	인돌린 유사체 및 이의 용도
TW201803871A (zh)	2016-06-24	2018-02-01	英塞特公司	作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JP7128264B2 (ja) *	2017-09-08	2022-08-30	ベイジーンリミテッド	ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体
WO2019079469A1 (en)	2017-10-18	2019-04-25	Incyte Corporation	CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
TW201924683A (zh)	2017-12-08	2019-07-01	美商英塞特公司	用於治療骨髓增生性贅瘤的低劑量組合療法
RS63806B1 (sr) *	2018-01-10	2023-01-31	Idorsia Pharmaceuticals Ltd	Derivati 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona i srodna jedinjenja kao modulatori c5a receptora za lečenje vaskulitisa i inflamatornih bolesti
SMT202200134T1 (it)	2018-03-08	2022-05-12	Incyte Corp	Composti di amminopirazindiolo come inibitori di pi3k-y
IL278889B2 (en) *	2018-06-01	2025-11-01	Incyte Corp	Dosing regimen for the treatment of pi3k related disorders
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
TWI727392B (zh) *	2018-08-13	2021-05-11	美商基利科學股份有限公司	噻二唑irak4抑制劑
CN110833552A (zh) *	2018-08-15	2020-02-25	广西梧州制药（集团）股份有限公司	吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
CR20250050A (es) *	2018-09-05	2025-03-19	Incyte Corp	Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
WO2022115762A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) *	2020-12-28	2021-10-01	青岛理工大学	用于海洋工程的劣化免疫仿生防护界面及制备方法
WO2023114369A2 (en)	2021-12-16	2023-06-22	Incyte Corporation	Topical formulations of pi3k-delta inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en) *	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es)	1998-08-11	2010-07-02	Novartis Ag	Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
KR100786927B1 (ko)	2000-06-28	2007-12-17	스미스클라인비이참피이엘시이	습식 분쇄방법
HUP0401982A3 (en)	2001-09-19	2012-09-28	Aventis Pharma Sa	Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
HU230798B1 (hu)	2001-10-30	2018-06-28	Novartis Ag	Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
PE20040522A1 (es)	2002-05-29	2004-09-28	Novartis Ag	Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
TWI335913B (en)	2002-11-15	2011-01-11	Vertex Pharma	Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
AR045944A1 (es)	2003-09-24	2005-11-16	Novartis Ag	Derivados de isoquinolina 1.4-disustituidas
EP1758892B1 (en)	2004-06-10	2012-10-17	Irm Llc	Compounds and compositions as protein kinase inhibitors
MX2007006204A (es)	2004-11-24	2007-06-20	Novartis Ag	Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
TWI423976B (zh)	2006-01-17	2014-01-21	Vertex Pharma	適合作為傑納斯激酶（ｊａｎｕｓｋｉｎａｓｅ）抑制劑之氮雜吲哚
TW200916447A (en)	2007-08-29	2009-04-16	Methylgene Inc	Sirtuin inhibitors
WO2009157880A1 (en)	2008-06-27	2009-12-30	S*Bio Pte Ltd	Pyrazine substituted purines
AR073651A1 (es) *	2008-09-24	2010-11-24	Novartis Ag	Formulaciones galenicas de compuestos organicos
CA2738429C (en) *	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
CN102395363A (zh)	2009-04-09	2012-03-28	肿瘤防护公司	Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物
CA2766100C (en)	2009-06-29	2018-05-22	Incyte Corporation	Pyrimidinones as pi3k inhibitors
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
PL2470546T3 (pl)	2009-08-28	2013-12-31	Takeda Pharmaceuticals Co	Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011130342A1 (en)	2010-04-14	2011-10-20	Incyte Corporation	FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011163195A1 (en)	2010-06-21	2011-12-29	Incyte Corporation	Fused pyrrole derivatives as pi3k inhibitors
ES2764848T3 (es)	2010-12-20	2020-06-04	Incyte Holdings Corp	N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012106343A2 (en)	2011-02-01	2012-08-09	The Board Of Trustees Of The University Of Illinois	Hdac inhibitors and therapeutic methods using the same
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) *	2011-09-02	2020-07-08	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI657090B (zh) *	2013-03-01	2019-04-21	英塞特控股公司	吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
WO2015191677A1 (en) *	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SI3831833T1 (sl) *	2015-02-27	2023-03-31	Incyte Holdings Corporation	Postopki za pripravo inhibitorja PI3K
IL278889B2 (en)	2018-06-01	2025-11-01	Incyte Corp	Dosing regimen for the treatment of pi3k related disorders
US11161838B2 (en) *	2018-11-13	2021-11-02	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors

2014
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-27 TW TW112117019A patent/TWI841376B/zh active
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 IL IL311666A patent/IL311666A/en unknown
- 2014-02-28 KR KR1020247033698A patent/KR20240152422A/ko active Pending
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active Active
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active Active
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2014-02-28 PH PH1/2021/552233A patent/PH12021552233A1/en unknown
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 SM SM20200043T patent/SMT202000043T1/it unknown
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active Active
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 KR KR1020237033761A patent/KR102717616B1/ko active Active
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en not_active Ceased
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920B1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321B1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
2020
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en not_active Abandoned
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en not_active Abandoned
- 2021-06-30 US US17/364,551 patent/US12152033B2/en active Active
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495B2/en active Active
- 2022-12-01 JP JP2022192954A patent/JP7556010B2/ja active Active
2024
- 2024-09-11 JP JP2024157116A patent/JP2025003975A/ja active Pending
- 2024-10-24 US US18/926,010 patent/US20250289823A1/en active Pending
- 2024-12-23 AU AU2024287194A patent/AU2024287194A1/en active Pending

Also Published As

Publication number	Publication date
JP2019142941A (ja)	2019-08-29
SI2961410T1 (sl)	2020-03-31
IL240784A0 (en)	2015-10-29
KR20210110409A (ko)	2021-09-07
US20190040067A1 (en)	2019-02-07
EA202192151A1 (ru)	2021-12-31
CA2901993A1 (en)	2014-09-04
TWI736135B (zh)	2021-08-11
PH12019501321A1 (en)	2020-10-12
PL2961410T3 (pl)	2020-05-18
SG11201506654UA (en)	2015-09-29
KR102298150B1 (ko)	2021-09-07
KR20220143146A (ko)	2022-10-24
KR20230145517A (ko)	2023-10-17
AU2020210278B2 (en)	2022-05-26
US20140249132A1 (en)	2014-09-04
CR20150472A (es)	2016-01-04
PH12015501920A1 (en)	2016-01-18
UA119641C2 (uk)	2019-07-25
IL283943B1 (en)	2023-04-01
AU2024287194A1 (en)	2025-01-23
TWI687220B (zh)	2020-03-11
CN109010343A (zh)	2018-12-18
EP3632442B1 (en)	2023-04-05
TW201929860A (zh)	2019-08-01
JP2023036609A (ja)	2023-03-14
BR112015020941A2 (pt)	2017-07-18
TWI657090B (zh)	2019-04-21
TW202214254A (zh)	2022-04-16
KR20150135327A (ko)	2015-12-02
IL283943B2 (en)	2023-08-01
TW202333734A (zh)	2023-09-01
IL267853A (en)	2019-09-26
TW201444846A (zh)	2014-12-01
EP2961410A1 (en)	2016-01-06
JP2016510035A (ja)	2016-04-04
MX2019010422A (es)	2019-10-15
US20220119393A1 (en)	2022-04-21
PH12021552233A1 (en)	2022-07-18
HRP20200263T1 (hr)	2020-05-29
JP2021020914A (ja)	2021-02-18
AU2022218495B2 (en)	2024-10-03
JP7556010B2 (ja)	2024-09-25
IL274771A (en)	2020-07-30
CY1122712T1 (el)	2021-03-12
MX2015011273A (es)	2015-12-03
PH12015501920B1 (en)	2016-01-18
US20250289823A1 (en)	2025-09-18
SG10201707130UA (en)	2017-10-30
KR102717616B1 (ko)	2024-10-16
WO2014134426A1 (en)	2014-09-04
AR094964A1 (es)	2015-09-09
SG10201912275YA (en)	2020-04-29
CN105120871B (zh)	2018-08-10
US20210332059A1 (en)	2021-10-28
IL301180A (en)	2023-05-01
AU2018264053A1 (en)	2018-12-06
EP3632442A1 (en)	2020-04-08
KR20240152422A (ko)	2024-10-21
IL283943A (en)	2021-07-29
EP4233869A3 (en)	2023-11-01
MX367713B (es)	2019-09-03
JP7189185B2 (ja)	2022-12-13
CL2015002442A1 (es)	2016-02-05
TW202019428A (zh)	2020-06-01
HUE047719T2 (hu)	2020-05-28
IL267853B (en)	2020-03-31
IL311666A (en)	2024-05-01
JP2025003975A (ja)	2025-01-14
EP2961410B1 (en)	2019-12-11
PH12019501321B1 (en)	2020-10-12
US12152033B2 (en)	2024-11-26
AU2018264053B2 (en)	2020-08-20
ES2945212T3 (es)	2023-06-29
CN105120871A (zh)	2015-12-02
CA2901993C (en)	2023-03-07
EP4233869A2 (en)	2023-08-30
AU2022218495A1 (en)	2022-09-08
RS59958B1 (sr)	2020-03-31
SMT202000043T1 (it)	2020-03-13
JP6545106B2 (ja)	2019-07-17
HK1221398A1 (en)	2017-06-02
KR102454308B1 (ko)	2022-10-14
AU2020210278A1 (en)	2020-08-20
PE20151996A1 (es)	2016-01-13
US20220106318A1 (en)	2022-04-07
MY177875A (en)	2020-09-24
TWI841376B (zh)	2024-05-01
PT2961410T (pt)	2020-03-02
KR102586858B1 (ko)	2023-10-11
EA201591612A1 (ru)	2016-05-31
DK2961410T3 (da)	2020-02-17
AU2014223257A1 (en)	2015-09-24
JP6776399B2 (ja)	2020-10-28
IL240784B (en)	2020-06-30
US9932341B2 (en)	2018-04-03
AU2014223257B2 (en)	2018-11-29
ES2774436T3 (es)	2020-07-21

Publication	Publication Date	Title
IL283943A (en)	2021-07-29	Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
LTC3057969I2 (lt)	2022-09-26	Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
PL3542798T3 (pl)	2025-09-08	Aceklidyna do zastosowania w leczeniu starczowzroczności
IL242610A0 (en)	2016-02-01	History of pyrazolopyrrolidine and their use in the treatment of diseases
ZA201507155B (en)	2017-01-25	Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
LT3121164T (lt)	2020-08-10	Sulfamoilpirolamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
PL2970101T5 (pl)	2025-12-15	Proleki fumaranów i ich zastosowanie w leczeniu różnych chorób
DK3811943T3 (da)	2023-04-03	Forbindelse til anvendelse til behandling af øjenlidelser
HUE061761T2 (hu)	2023-08-28	Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
HUE065346T2 (hu)	2024-05-28	Macskafélék anyagcserezavarainak kezelése
PL3004108T3 (pl)	2018-03-30	Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
DK2838539T3 (da)	2017-11-27	Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
PL3466425T3 (pl)	2021-04-06	Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
IL245698B (en)	2019-11-28	2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
PL3004112T3 (pl)	2018-02-28	Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
PL3236960T3 (pl)	2025-07-07	Fluralaner do zastosowania w leczeniu demodekozy
PL2988750T5 (pl)	2025-09-22	Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
HUE045148T2 (hu)	2019-12-30	Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére
PL2948137T3 (pl)	2019-02-28	Sposoby leczenia zwłóknienia i nowotworów
HRP20190219T1 (hr)	2019-03-22	Spojevi za tretman pretilosti i postupci za njihovu uporabu
SI2986325T1 (sl)	2020-02-28	Postopki zdravljenja motenj ciklusa sečnine
IL246148A0 (en)	2016-07-31	Treating brain disorders and biomarkers related thereto
HUE042691T2 (hu)	2019-07-29	Tiazolo-pirimidinon felhasználása gyulladásos bélbetegségek kezeléséhez
HRP20181181T1 (hr)	2018-10-19	Postupak obrade i liječenja lišmenioze uporabom feksinidazola